Helicobacter pylori (Hp) infection is a major cause of chronic gastritis and gastric cancer, and the increasing antibiotic resistance of conventional therapies poses a serious challenge. To evaluate the alleviating effects of different components of Lactobacillus fermentum TY H27 on inflammation induced by Hp infection, an in vitro model of Hp infected GES 1 cells was established. The cells were treated with live bacteria, supernatant, crude lysate, inactivated bacterial cells, or lysed bacterial preparation, respectively. Cell viability and Interleukin-8 (IL 8) secretion were measured. Furthermore, an Hp infected C57BL/6J mouse model was established, and the mice were treated with triple therapy drugs or TY H27 lysed preparation. Serum inflammatory cytokine levels and gastric mucosal pathological changes were assessed. The results showed that the TY H27 lysed preparation significantly inhibited Hp induced IL 8 secretion, reducing it from 28.53 pg·mL?1 in the model group to 17.81 pg·mL?1 (a reduction of 37.57%). In vivo, the lysed preparation decreased serum Interleukin-6 (IL 6)from 30.81 pg·mL?1 to 19.99 pg·mL?1 (a reduction of 35.12%) and C-X-C motif chemokine ligand 1 (CXCL1)from 35.12 pg·mL?1 to 22.72 pg·mL?1 (a reduction of 35.31%). The gastric mucosal inflammatory infiltration score decreased from 3.17 to 1.33 (a reduction of 58.04%), and the mucosal injury score decreased from 3.33 to 1.50 (a reduction of 54.95%), with effects comparable to those of the triple therapy group (P>0.05). In contrast, the supernatant, crude lysate, and inactivated bacterial cells showed no significant anti inflammatory effects in vitro. In conclusion, the TY H27 lysed preparation effectively alleviates Hp induced inflammation and improves gastric mucosal injury, providing a solid theoretical basis for the development of anti H. pylori functional foods and adjunctive postbiotic agents based on Lactobacillus fermentum TY H27 lysate.